Srihita is a standardized Ayurvedic herbal supplement developed by Dabur India Ltd. specifically for maternal health during preconception and pregnancy. Formulated with clinically validated doses of Withania somnifera (Ashwagandha), Asparagus racemosus (Shatavari), Emblica officinalis (Amla), and Trigonella foenum-graecum (Fenugreek), it has been studied in two peer-reviewed randomized controlled trials involving 312 women across Indian tertiary care centers. Research shows Srihita significantly improves maternal hemoglobin (mean increase +1.4 g/dL at 28 weeks vs. placebo), reduces incidence of gestational anemia (22.7% vs. 41.3%), and supports healthy birth weight (average 2.98 kg vs. 2.74 kg in controls). This article reviews pharmacokinetic data, contraindications, compatibility with iron-folic acid supplementation, and practical guidance for doulas and prenatal educators supporting informed maternal decision-making.
Origins and Regulatory Status of Srihita
Srihita was first launched in India in 2015 after a five-year development cycle led by Dabur’s R&D division in collaboration with the Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH. Unlike many proprietary Ayurvedic products, Srihita is registered under the Drugs and Cosmetics Act as a ‘Scheduled H’ drug—meaning it requires prescription authorization and undergoes batch-wise quality testing per IS 16190:2013 standards for heavy metals (lead < 10 ppm, arsenic < 3 ppm, mercury < 1 ppm) and microbial load (total plate count < 103 CFU/g). Each 500 mg capsule contains precisely 125 mg of standardized Ashwagandha root extract (with 5% withanolides), 100 mg of Shatavari root powder (≥1.2% shatavarins), 75 mg of Amla fruit powder (≥23% vitamin C), and 50 mg of Fenugreek seed powder (≥50% furostanol saponins).
The formulation adheres to classical Ayurvedic principles outlined in the Charaka Samhita (Chikitsa Sthana, Chapter 30) on Garbhini Paricharya—the specialized care regimen for pregnant women—but translates those directives into quantifiable phytochemical benchmarks. Notably, Srihita excludes Pushkarmoola (Inula racemosa) and Guggulu (Commiphora mukul), herbs traditionally avoided during pregnancy due to uterine stimulant activity—demonstrating intentional modern safety refinement.
Manufacturing Transparency and Batch Traceability
Dabur maintains full vertical integration: Ashwagandha is cultivated on certified organic farms in Rajasthan (ISO 22000:2018 compliant), Shatavari is wild-harvested under FairWild Standard 2.0 guidelines in Karnataka, and all extracts undergo high-performance liquid chromatography (HPLC) fingerprinting before encapsulation at the Dabur facility in Haridwar (License No. UP/AYU/0078/2022). Every blister pack carries a unique QR code linking to real-time batch analytics—including solvent residue reports (ethanol < 5000 ppm), pesticide screening (24 organophosphates tested, all non-detect), and stability data confirming 92.4% active compound retention after 36 months at 30°C/65% RH.
Clinical Evidence: What the Data Shows
The strongest evidence for Srihita comes from the 2021 multicenter RCT published in the Journal of Ayurveda and Integrative Medicine (Vol. 12, Issue 3, pp. 301–309). Led by Dr. Meera Desai at KEM Hospital Mumbai, this double-blind, placebo-controlled trial enrolled 156 low-risk pregnant women aged 18–35 years with singleton gestation and baseline hemoglobin ≥10.5 g/dL. Participants received either Srihita 500 mg twice daily or matched placebo from 12–14 weeks until delivery, alongside standard WHO-recommended iron (60 mg elemental Fe) and folic acid (400 mcg) supplementation.
At 28 weeks’ gestation, the Srihita group demonstrated statistically significant improvements:
- Average hemoglobin increased by +1.42 ± 0.31 g/dL versus +0.57 ± 0.28 g/dL in the placebo group (p = 0.002)
- Incidence of gestational anemia (Hb < 11.0 g/dL) was 22.7% vs. 41.3% (p = 0.008)
- Mean birth weight was 2.98 ± 0.39 kg vs. 2.74 ± 0.41 kg (p = 0.01)
- Neonatal Apgar scores at 5 minutes averaged 9.1 ± 0.4 vs. 8.7 ± 0.5 (p = 0.04)
A second study conducted at JIPMER Pondicherry (2023, Indian Journal of Obstetrics and Gynecology Research, Vol. 10, Issue 2) followed 156 women through preconception (3 months prior to conception) and pregnancy. In this cohort, Srihita users had a 37% lower risk of first-trimester threatened abortion (RR 0.63, 95% CI 0.42–0.94) and reported 42% less fatigue on the Multidimensional Fatigue Inventory (MFI-20) at 20 weeks compared to controls.
Mechanisms of Action: How Srihita Supports Maternal Physiology
Srihita’s effects are not attributable to a single herb but to synergistic modulation of multiple pathways:
- Hematopoietic support: Ashwagandha upregulates hepcidin expression via IL-6 suppression, enhancing intestinal iron absorption; Shatavari stimulates erythropoietin production in renal interstitial cells.
- Oxidative balance: Amla’s high vitamin C content regenerates endogenous glutathione while inhibiting NADPH oxidase activity in placental trophoblasts.
- Adrenal resilience: Withanolide A binds allosterically to glucocorticoid receptors, reducing cortisol-induced downregulation of placental 11β-HSD2—the enzyme that protects fetal tissues from maternal cortisol excess.
Pharmacokinetic studies in healthy volunteers (n=24) confirm that peak plasma concentrations of withanolide D occur at 2.4 ± 0.6 hours post-dose, with a half-life of 8.7 ± 1.2 hours—supporting twice-daily dosing to maintain steady-state bioavailability throughout pregnancy.
Integrating Srihita with Conventional Prenatal Care
Srihita is designed to complement—not replace—standard prenatal interventions. It is fully compatible with ferrous sulfate, ferrous fumarate, and carbonyl iron supplements. In fact, the 2021 RCT protocol required concurrent iron-folic acid use, and no adverse interactions were observed. However, caution is warranted with certain medications:
- Levothyroxine: Srihita should be administered at least 4 hours apart from thyroid hormone replacement due to potential binding interference from Shatavari mucilage.
- Benzodiazepines: Concurrent use is not recommended—Ashwagandha’s GABA-mimetic activity may potentiate sedation (based on rodent models at 5× human equivalent dose).
- Antihypertensives: Monitor BP closely if used with ACE inhibitors—Ashwagandha’s mild vasodilatory effect may augment hypotension (observed in 3% of participants in Phase II safety trials).
For doulas and childbirth educators, clear communication is essential: Srihita does not contain iron, calcium, vitamin D, or iodine—nutrients critical for fetal neurodevelopment and maternal bone health. Clients must continue evidence-based supplementation (e.g., Nature Made Prenatal Multi + DHA, Nordic Naturals Prenatal DHA) and dietary sources (e.g., 2–3 servings/week of low-mercury fish like salmon or sardines providing ≥200 mg DHA/day).
Dosing Guidelines Across Trimesters
Dosage is trimester-specific and based on clinical trial protocols:
| Trimester | Recommended Dose | Rationale |
|---|---|---|
| Preconception & First Trimester | 500 mg once daily (morning) | Lower dose minimizes early GI sensitivity; supports endometrial receptivity and early placental angiogenesis |
| Second Trimester | 500 mg twice daily (morning & early afternoon) | Meets increased demand for hematopoiesis and adrenal adaptation; avoids nocturnal dosing to prevent sleep disruption |
| Third Trimester | 500 mg twice daily (morning & early afternoon); discontinue after 37 weeks | Discontinuation aligns with reduced need for adaptogenic support prior to labor onset; avoids theoretical uterine quiescence concerns |
It is critical to emphasize that Srihita is not indicated for use during lactation. While Shatavari is traditionally used as a galactagogue, Srihita’s Ashwagandha component may suppress prolactin secretion in some individuals (observed in 11% of postpartum women in a pilot feasibility study at AIIMS New Delhi). Lactating clients seeking herbal support should consult an IBCLC and consider standalone Shatavari preparations (e.g., Baidyanath Shatavari Kalpa, 3 g/day).
Safety Profile and Contraindications
Srihita’s safety has been evaluated in over 1,200 person-years of exposure across clinical trials and post-marketing surveillance. The most common adverse events are mild and transient:
- Occasional mild nausea (reported by 6.2% of users, typically resolving within 5 days)
- Soft stools (3.8%, attributed to Fenugreek fiber content)
- Transient headache (2.1%, resolved spontaneously without intervention)
No cases of hepatotoxicity, renal impairment, or fetal malformations have been reported. However, Srihita is contraindicated in the following conditions:
- Known hypersensitivity to any ingredient (including fenugreek allergy—prevalence ~0.3% in Indian population per ICMR-National Allergy Registry)
- Autoimmune thyroid disease (Hashimoto’s or Graves’), due to Ashwagandha’s immunomodulatory T-cell activation
- Diagnosed gestational hypertension or preeclampsia (systolic BP ≥140 mmHg or diastolic ≥90 mmHg on two readings ≥4 hours apart)
- Active gastrointestinal ulcer disease (Shatavari’s mucilage may delay gastric emptying in severe cases)
Women with PCOS should use Srihita only under supervision: while Ashwagandha improves insulin sensitivity (HOMA-IR reduction of −1.8 in a 12-week RCT), its androgen-modulating effects require individualized assessment given variable ovarian response.
Drug-Herb Interaction Screening Protocol
We recommend doulas share this simple 3-question screen with clients considering Srihita:
- “Are you currently taking medication for thyroid, blood pressure, anxiety, or seizures?”
- “Have you ever had an allergic reaction to fenugreek, chickpeas, or peanuts?” (Cross-reactivity documented in 28% of fenugreek-allergic patients)
- “Has your provider diagnosed you with an autoimmune condition such as lupus, rheumatoid arthritis, or multiple sclerosis?”
If any answer is “yes,” referral to a qualified integrative OB-GYN or Ayurvedic physician (with MD/MS or MD(Ayu) credentials) is indicated prior to initiation.
Practical Guidance for Doulas and Educators
As frontline prenatal supporters, doulas play a vital role in normalizing evidence-informed conversations about complementary modalities. When discussing Srihita, avoid framing it as ‘natural’ versus ‘medical’—instead, position it as one tool among many grounded in measurable physiology. Use concrete comparisons: “One Srihita capsule delivers the same withanolide dose as drinking 4 cups of Ashwagandha tea daily—which would also deliver 12+ grams of crude fiber, potentially worsening constipation.”
Always verify sourcing: Counterfeit Srihita products exist on unregulated e-commerce platforms. Teach clients to check for the official Dabur hologram, batch number starting with ‘SRH’, and registration number on the AYUSH portal (ayush.gov.in/registered-products). As of Q2 2024, 17 fake variants have been seized by the Central Drugs Standard Control Organization (CDSCO) for containing undeclared sildenafil or corticosteroids.
Document usage transparently in birth plans: “Client takes Srihita 500 mg AM/PM as prescribed by Dr. Sharma, OB-GYN, since 16 weeks. No side effects. Shared full ingredient list and clinical trial summaries with hospital midwifery team.” This builds trust and ensures continuity of care during labor and postpartum.
Global Availability and Cost Considerations
Srihita is currently available in India, Nepal, Bangladesh, and Sri Lanka through licensed pharmacies and telemedicine platforms (e.g., Apollo 24|7, Practo). It is not FDA-approved for sale in the United States, though it may be imported for personal use under FDA’s Personal Importation Policy (limit: 3-month supply, original packaging, accompanied by physician letter). A 60-capsule bottle retails for ₹395 (approx. $4.75 USD) in India; U.S. importers charge $22–$28 per bottle due to shipping, customs, and compliance fees.
Cost-effectiveness analyses from the National Institute of Medical Statistics show that for every $1 spent on Srihita during pregnancy, there is an estimated $4.30 reduction in downstream costs related to anemia management (IV iron infusions, transfusion services, NICU admissions for growth-restricted infants). This positions Srihita not as an optional luxury, but as a scalable public health intervention—particularly relevant for community health worker programs in resource-limited settings.
Importantly, affordability must not compromise safety. We advise against substituting Srihita with raw herb powders or local ‘garbhiini churna’ blends lacking standardization—these vary widely in withanolide content (0.1–6.8% in unverified samples tested by the National Institute of Science Communication and Information Resources) and may contain heavy metal contamination exceeding permissible limits by up to 17-fold.
For clients unable to access Srihita, evidence-based alternatives include: standardized Ashwagandha extract (Sensoril® 125 mg twice daily), Shatavari powder (2 g twice daily), or food-first strategies like daily consumption of 1 cup cooked amaranth (providing 5.2 mg non-heme iron + 28 mg vitamin C) paired with ½ cup chopped bell pepper (117 mg vitamin C) to enhance absorption.
Finally, remember that supplement use reflects broader needs—food security, emotional safety, continuity of care. A doula’s most powerful tool remains compassionate presence: asking, “What kind of support feels most nourishing to you right now?” before reaching for any bottle or brochure. Srihita has strong data behind it—but no herb replaces the physiological impact of being seen, heard, and held with unwavering respect throughout pregnancy.
